Maintaining and strengthening business relationships through strategic shareholdings
First written in FY2018. 6 of 7 entries say "Advanced", first in FY2019. Latest entry: FY2026.
The whole theme swung hardest in 2019: 17 of 136 companies on the "Worse" side.
68 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Unlisted stocks: 6; 2,839; investment primarily for exploring business opportunities」
The company continued its annual review of the economic rationale and purpose of its cross-shareholdings and acquired 6 unlisted stocks for ¥2,839 million. Meanwhile, it transferred shares in connection with the return of shares held in a retirement benefit trust and sold 1 stock. - FY2025AdvancedAnnual report
「Unlisted stocks: 4; 985; investment primarily for exploring business opportunities」
The company continued its annual review of the economic rationale and purpose of its cross-shareholdings and acquired 4 unlisted stocks for a total acquisition cost of ¥985 million. Meanwhile, it reduced its holdings of 7 listed stocks. - FY2024AdvancedAnnual report
「Stocks whose number of shares increased during the fiscal year: Unlisted stocks, 6; total acquisition cost for the increase in shares: 2,162; investment primarily for exploring business opportunities」
The company continued its annual review of the economic rationale and purpose of its cross-shareholdings and invested ¥2,162 million to acquire 6 unlisted stocks, primarily to explore business opportunities. - FY2023AdvancedAnnual report
「Holdings whose number of shares decreased during the fiscal year」
The company continued to review the economic rationale and purpose of its cross-shareholdings and reduced its holdings of 1 unlisted stock and 4 listed stocks during the fiscal year. - FY2020AdvancedAnnual report
「The company held the shares to explore business opportunities in the Cardiovascular Company, but following its review, sold all of them in May 2020 and held no shares as of the filing date.」
Following a review of the purpose and economic rationale of its cross-shareholdings, the company sold all shares in ShockWave Medical in May 2020. - FY2019AdvancedAnnual report
「With respect to the shares held, the company verifies their economic rationale and purpose from a medium- to long-term perspective each year at meetings of the Board of Directors and other bodies.」
The company stated that, in addition to maintaining and strengthening business relationships, it conducts annual reviews of the economic rationale and purpose of its cross-shareholdings through the Board of Directors and other bodies. - FY2018First statedAnnual report
「The group has designated the shares it holds to expand its earnings base by maintaining and strengthening business relationships with business partners as financial assets measured at fair value through other comprehensive income.」
The company explicitly identified maintaining and strengthening business relationships and expanding its earnings base as the purposes for holding cross-shareholdings.